NFE2L2 and melanoma: Constitutive activation of NRF2, mainly due to inactivating mutations on the KEAP1 gene or gain-of-function mutations on the NFE2L2 gene, that occur in several different kinds of tumors (e.g., lung, melanoma, hepatocellular carcinoma), may act as a driver of cancer progression, metastasis, and resistance to therapies [71].